Last €2.57 EUR
Change Today -0.021 / -0.81%
Volume 255.3K
COX On Other Exchanges
Symbol
Exchange
EN Paris
Frankfurt
OTC US
As of 11:35 AM 05/24/13 All times are local (Market data is delayed by at least 15 minutes).

nicox sa (COX) Snapshot

Open
€2.61
Previous Close
€2.59
Day High
€2.62
Day Low
€2.57
52 Week High
01/23/13 - €3.75
52 Week Low
07/25/12 - €2.12
Market Cap
187.1M
Average Volume 10 Days
447.6K
EPS TTM
€-0.26
Shares Outstanding
72.8M
EX-Date
05/30/99
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for NICOX SA (COX)

Related News

No related news articles were found.

nicox sa (COX) Related Businessweek News

No Related Businessweek News Found

nicox sa (COX) Details

NicOx S.A. develops a portfolio of therapies and diagnostic tools to enhance sight in the United States, Europe, and internationally. It provides AdenoPlus a diagnostic test that offers eyecare professionals to diagnose and manage patients with an acute red eye. The company’s pipeline product, Latanoprostene bunod, is in Phase III clinical trails for the treatment of glaucoma and ocular hypertension. In addition, it engages in the research and development of nitric oxide steroids for the treatment of back and front of the eye disease; and NO-donors for eye disorder applications. Further, the company develops Naproxcinod, an anti-inflammatory candidate that is in regulatory review with the US Food and Drug Administration for the treatment of signs and symptoms of osteoarthritis; nitric oxide for cardiovascular indications; and NCX 1047, a dermatology anti-inflammatory drug-candidate, which is in preclinical stage of development. NicOx S.A. has collaboration with Bausch + Lomb, Merck, and Grupo Ferrer Internacional S.A. The company was founded in 1996 and is headquartered in Sophia Antipolis, France.

44 Employees
Last Reported Date: 05/15/13
Founded in 1996

nicox sa (COX) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

nicox sa (COX) Key Developments

Nicox SA Announces Consolidated Earnings Results for the First Quarter Ended March 31, 2013

Nicox SA announced consolidated earnings results for the first quarter ended March 31, 2013. For the quarter, the company’s revenues totaled EUR 0.07 million, compared to EUR 7.5 million for the same period of 2012, which included receipt of a significant milestone payment from Bausch + Lomb. Net loss was EUR 4.3 million compared to a net profit of EUR 4.2 million for the three months to March 31, 2012. This situation is explained by the strong decrease in revenues recognized over the period compared to the first three months of 2012 which included a significant milestone payment from partner Bausch + Lomb. Operating loss was EUR 4.3 million, compared to an operating profit of EUR 4 million on March 31, 2012. Loss before income tax was EUR 4,289,000 compared to profit before income tax of EUR 4,181,000 a year ago.

Nicox SA Nominates Vicente Anido, Jr. for Election to its Board of Directors

Nicox S.A. announced that the Company's Board of Directors has nominated Vicente Anido, Jr., PhD., to be elected to the Board. Dr. Anido is a highly respected and experienced leader in the ophthalmology sector. He most recently served as President and Chief Executive Officer of ISTA Pharmaceuticals prior to its acquisition by Bausch + Lomb. The election of Dr. Anido to Nicox's Board will be voted on at the Company's 2013 Ordinary Shareholder Meeting, which will be convened for June 6, 2013. From 2001 to 2012, Dr. Anido was President, Chief Executive Officer and a Director of ISTA Pharmaceuticals.

Nicox Eyes Acquisition Opportunities

Nicox SA reported cash flow of €77.5 million on December 31, 2012. The company is looking for acquisition opportunities. The company stated that it is evaluating merger and acquisition opportunities, product acquisitions and licensing agreements for products at an advanced stage of development or already marketed. The company is already negotiating with potential partners.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
COX:FP €2.57 EUR -0.021

COX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for COX.
View Industry Companies
 

Industry Analysis

COX

Industry Average

Valuation COX Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NICOX SA, please visit www.nicox.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.